Symbiosis appoints David Collins as Commercial Director

Headshot of David Collins, member of the Symbiosis Leadership team with Symbiosis background

Symbiosis appoints David Collins as Commercial Director

January 2023, Stirling, Scotland.


Symbiosis Pharmaceutical Services, the Scotland-based biotech/pharma CMO, has appointed David Collins as Commercial Director to support its continued expansion programme.


Collins will lead Symbiosis’ commercial efforts as it seeks to grow its commercial offering aligned with its ongoing operational and service expansion rollout.


Collins will be particularly responsible for commercial operations worldwide, overseeing both business development and marketing as the company seeks to grow its customer base in both North America and Europe over the coming years. An initial objective is for David to utilise his experience to help launch the company’s new analytical testing services range which will come online in the next few months.


Collins has over 25 years of commercial experience offering scientific services to the pharmaceutical and biotech industries.


Before joining Symbiosis Collins was responsible for all business development planning, processes and activities at Ncardia and has experience working for Charles River Laboratories and the Aptamer Group.


Collins said: “I am pleased to be joining Symbiosis at this exciting juncture in its history as the company is in the process of expansion. With the successful development of ATMPs, and the high-level expertise needed to handle toxic and highly potent compounds, we are seeing a greater demand for contract services and an increased need for specialist manufacturing partners to support clinical-stage drug development and commercial batches of niche and orphan products.


“It is this creative and innovative approach that will further differentiate Symbiosis from its competitors and enable it to continue to grow. I am genuinely excited to be part of the talented team at Symbiosis.”


Colin MacKay, Chief Executive Officer at Symbiosis, said: “David has a strong track record of commercial strategy and business development making him a valuable asset to the company during its next phase of growth. Having developed and implemented successful go-to-market plans and growth strategies targeting international markets, he is a perfect addition to the team at a time when the company is ramping up its global marketing and sales efforts.”

Sign up to our Newsletter

Fill in your details to be added to our mailing list and receive our latest updates.